Letter by Sherratt Regarding Article, “Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy”
- 15 November 2022
- journal article
- letter
- Published by Wolters Kluwer Health in Circulation
- Vol. 146 (20) , E282-E283
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker SubstudyCirculation, 2022
- Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studiesEuropean Heart Journal Supplements, 2020
- Low-Dose Methotrexate for the Prevention of Atherosclerotic EventsNew England Journal of Medicine, 2019
- Cardiovascular Risk Reduction with Icosapent Ethyl for HypertriglyceridemiaNew England Journal of Medicine, 2019
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008